View all news

Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

June, 01, 2021

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that members of its management team will participate in a fireside chat and one-on-one investor meetings at the virtual Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 5:30 p.m. ET.

The fireside chat will be webcast live on the Events and Presentations page under the investor relations section of Edgewise Therapeutic’s website at https://investors.edgewisetx.com/events-and-presentations and accessible for 90 days following the presentation. It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.To learn more, go to: www.edgewisetx.com or follow us on LinkedIn.

Investors & Media
Michael Carruthers
Chief Financial Officer
ir@edgewisetx.com

Source: Edgewise Therapeutics, Inc.

Multimedia Files:

Categories: Press Releases
View all news